Paid Clinical Trials Madison

Discover 558 paid clinical trials in Madison, Wisconsin. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 558

BIIB091 & DRFA Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting

PHASE2

Sponsor:

Biogen

Location:

Madison WI, Milwaukee WI, Fort Wayne IN, Saint Louis MOshow 19 more

Code:

NCT05798520

Conditions

Relapsing Forms of Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

BIIB091

DRF

Placebo

IMM-1-104A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Recruiting

PHASE1

PHASE2

Sponsor:

Immuneering Corporation

Location:

Madison WI, Chicago IL, Rochester MN, Nashville TNshow 15 more

Code:

NCT05585320

Conditions

Advanced Solid Tumor

Pancreatic Adenocarcinoma

Malignant Melanoma (Cutaneous)

Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IMM-1-104 Monotherapy (Treatment Group A)

IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)

IMM-1-104 + modified FOLFIRINOX (Treatment Group C)

IMM-1-104 + dabrafenib (Treatment Group D)

IMM-1-104 + pembrolizumab (Treatment Group E)

Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Madison WI, Johnson Creek WI, Janesville WI, Summit WIshow 715 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Recruiting

PHASE3

Sponsor:

SWOG Cancer Research Network

Location:

Madison WI, Janesville WI, Summit WI, Oconomowoc WIshow 530 more

Code:

NCT04071457

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide

Daratumumab/rHuPH20

FAPI PET/MRIUsing FAPI PET/MRI to Evaluate Prostate Cancer

Recruiting

PHASE2

Sponsor:

University of Wisconsin, Madison

Location:

Madison WI

Code:

NCT06675357

Conditions

Prostate Cancer Metastatic Disease

Prostate Cancers

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

FAPI

Positron Emission Tomography (PET)

Magnetic Resonance Imaging

Selumetinib vs. Carboplatin/VincristineA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Madison WI, Milwaukee WI, Chicago IL, Iowa City IAshow 104 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

CamizestrantAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Madison WI, Milwaukee WI, Appleton WI, Park Ridge ILshow 143 more

Code:

NCT05952557

Conditions

Breast Cancer, Early Breast Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Camizestrant

Tamoxifen

Anastrozole

Letrozole

Exemestane

Nivolumab, Ipilimumab, CabozantinibTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Summit WI, Oconomowoc WI, Mukwonago WI, Waukesha WIshow 368 more

Code:

NCT03866382

Conditions

Bladder Adenocarcinoma

Bladder Clear Cell Adenocarcinoma

Bladder Mixed Adenocarcinoma

Bladder Neuroendocrine Carcinoma

Bladder Small Cell Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography Test

GS-1811 & ZimberelimabStudy of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Recruiting

PHASE1

Sponsor:

Gilead Sciences

Location:

Madison WI, Nashville TN, Toronto, Dallas TXshow 6 more

Code:

NCT05007782

Conditions

Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Denikitug

Zimberelimab

ONC201ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Recruiting

PHASE3

Sponsor:

Chimerix

Location:

Madison WI, Chicago IL, Iowa City IA, Rochester MNshow 53 more

Code:

NCT05580562

Conditions

H3 K27M

Glioma

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Dordaviprone (ONC201)

Dordaviprone (ONC201) + Placebo

Placebo